TVTX
Travere Therapeutics
$56.68
−$0.68 (−1.19%)Jul 27, 2026
Key metrics
The numbers that frame TVTX today
- Market cap
- $5.27B
- P/E (TTM)
- -246.0
- EV / FCF
- -190.8
- Gross margin
- 98.6%
- EV / Sales
- 10.3
- ROIC
- -1.9%
- Div yield
- 0%
- Debt / equity
- 3.3
- 52wk Low
- $15.03
- 52wk High
- $60.10
Growth
Revenue and earnings trend for TVTX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about TVTX
Is Travere Therapeutics a good buy?
Yes. Travere Therapeutics has strong quality and excellent momentum. Both signals support the setup. Growth looks poor, a caveat that does not overturn the setup. We think Travere Therapeutics is selling at a high price, which cuts against the buy case.
What is the market capitalization of TVTX?
Travere Therapeutics's market capitalization is $5.27B.
What is the P/E ratio for TVTX stock?
Travere Therapeutics's current P/E ratio is -246.
What is the 52-week high for TVTX stock?
The 52-week high for Travere Therapeutics is $60.10. The current close of $56.68 is 5.7% below that high.
What is the 52-week low for TVTX stock?
The 52-week low for Travere Therapeutics is $15.03. The current close of $56.68 is 277.1% above that low.
Does TVTX stock pay dividends?
Travere Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for TVTX?
Travere Therapeutics's Debt / Equity ratio is 3.32.